An episignature informed systematic analysis to ascertain the clinical significance and consequences of CHD8 missense variants.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Godfrey Molly, Levy Michael A, Campbell Christopher, Demain Leigh, Jenkinson Sarah, Hilton Sarah, Almoguera Berta, Balasubramanian Meena, Bijlsma Emilia K, Blanco-Kelly Fiona, Burkitt Wright Emma M M, Cappuccio Gerarda, Chandler Kate E, Devriendt Koen, Diaz de Bustamante Aranzazu, Haanpää Maria K, Hörnig Carolin, Jones Elizabeth A, Kocagil Sinem, Koillinen Hannele, Lakshmi Narayanan Dhanya, Leonardi Emanuela, Madhu Rajesh, Majethia Purvi, Murgia Alessandra, Rosser Elisabeth, Schuelke Markus, Shukla Anju, Soengas-Gonda Emma, Stewart Sarah, Sznajer Yves, Tahsin Swafiri Saoud, Venancio Maria Margarida, Guerrini Renzo, Montomoli Martino, Vetro Annalisa, Wright Thomas, Gokhale David, Sadikovic Bekim, Douzgou Houge Sofia, Banka Siddharth
Аннотация
Pathogenic CHD8 variants cause autosomal dominant 'Intellectual developmental disorder with autism and macrocephaly' (IDDAM) and are amongst the most common monogenic causes of autism. The clinical significance of CHD8 missense variants (MVs) frequently remains uncertain. Systematically applying ACGS/ACMG guidelines to 36 CHD8 MVs in 39 affected patients, only two variants were classified likely pathogenic (LP), with the remaining 34 classified variants of uncertain significance (VUS). We subclassified the variants according to posterior probability of pathogenicity (PPP), with 14 being at least tepid VUS (PPP ≥ 50%). Comprehensive phenotypic analysis revealed no discernible clinical differences between individuals carrying at least tepid VUS and others, offering no additional insight for variant classification. EpiSign™ testing revealed a CHD8-IDDAM episignature, as previously detected in patients with truncating/null variants, in 11 cases, allowing reclassification of 8 VUS (all previously classified at least tepid) as LP. Molecular modelling indicated that disease-causing (LP/P) CHD8 MVs are concentrated in structured and/or functional protein domains. Compared to truncating/null variants, disease-causing MVs were less often associated with attention issues and macrocephaly, but clinical features were otherwise similar. Additionally, three disease-causing MVs were inherited from unaffected/mildly affected parents. Overall, we show that determining the clinical significance of CHD8 MVs is challenging, even with detailed clinical information, but that incorporating episignature analysis increases diagnostic yield. Further, our results indicate that CHD8 MVs are likely to act via a loss-of-or reduced function mechanism. These findings reveal the importance and complexity of interpreting CHD8 MVs and will improve the diagnosis and understanding of CHD8-related disorders.